Abivax Raises Price Target and Launches $600 Million Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: stocktwits
- Price Target Increase: BTIG raised its price target for Abivax from $150 to $175 while maintaining a Buy rating, reflecting confidence in the new drug obefazimod's safety data, indicating a potential upside of about 31% from the current stock price.
- FDA Risk Concerns: Wedbush analyst increased the price target from $90 to $110 but kept a Neutral rating due to concerns about how the FDA will assess cancer risk and the potential for a Black Box warning, suggesting a possible downside of around 17% from the stock's closing price.
- Public Offering Announcement: Abivax announced the launch of an underwritten public offering of approximately $600 million in American Depositary Shares, intending to use the net proceeds for U.S. commercialization and clinical development of obefazimod, indicating a proactive approach to future growth.
- Positive Market Sentiment: On Stocktwits, retail sentiment around ABVX remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', reflecting investor confidence in the company's ability to move forward independently and expectations for a potential buyout.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 96.150
Low
131.00
Averages
150.71
High
175.00
Current: 96.150
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Shares Surge 25% on Positive Drug Trial Data
- Stock Recovery: Shares of French biotech company Abivax surged 25% on Tuesday, successfully reversing a 44% drop earlier this month due to clinical trial data concerns, indicating a regained market confidence in its drug prospects.
- Clinical Trial Results: The latest late-stage trial data revealed that obefazimod's remission rates for ulcerative colitis patients were in line with expected background rates, alleviating investor fears regarding cancer risks, although uncertainties remain.
- Analyst Insights: Jefferies analysts described the update as 'supportive,' yet expressed skepticism about whether it would restore investor confidence, citing the difficulty in discounting cancer risks and challenges related to cash needs and sparse catalyst pathways.
- Acquisition Potential: Abivax is viewed as a prime acquisition target, with unverified rumors suggesting interest from several Big Pharma companies, further enhancing its strategic significance in the biotech landscape.
See More
Abivax Raises Price Target and Launches $600 Million Public Offering
- Price Target Increase: BTIG raised its price target for Abivax from $150 to $175 while maintaining a Buy rating, reflecting confidence in the new drug obefazimod's safety data, indicating a potential upside of about 31% from the current stock price.
- FDA Risk Concerns: Wedbush analyst increased the price target from $90 to $110 but kept a Neutral rating due to concerns about how the FDA will assess cancer risk and the potential for a Black Box warning, suggesting a possible downside of around 17% from the stock's closing price.
- Public Offering Announcement: Abivax announced the launch of an underwritten public offering of approximately $600 million in American Depositary Shares, intending to use the net proceeds for U.S. commercialization and clinical development of obefazimod, indicating a proactive approach to future growth.
- Positive Market Sentiment: On Stocktwits, retail sentiment around ABVX remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', reflecting investor confidence in the company's ability to move forward independently and expectations for a potential buyout.
See More
Abivax Launches $600 Million Public Offering of ADS
- Offering Size: Abivax has announced the launch of a public offering of approximately $600 million (about €527 million) of American Depositary Shares (ADS), indicating the company's proactive approach to capital raising aimed at supporting its drug development and commercialization efforts.
- Share Issuance: The offering will be conducted through a capital increase without preferential subscription rights, which is expected to attract investor interest, particularly given the positive progress of the company's drug candidates in clinical trials.
- Use of Proceeds: The company intends to use the net proceeds from the offering for the commercialization of its lead drug candidate, obefazimod, clinical research, and general corporate purposes, reflecting its focus on future market opportunities.
- Market Response: The final size and pricing of the offering will be determined during the upcoming book-building process, with market conditions influencing the timing of completion, demonstrating the company's sensitivity to market dynamics.
See More
Abivax Launches $600 Million Underwritten Public Offering
- Offering Size: Abivax SA announced a public offering of approximately $600 million of American Depositary Shares (ADS), each with a nominal value of €0.01, reflecting the company's confidence in capital markets and its aim to raise funds for future growth.
- Underwriter Option: The company expects to grant underwriters an option to purchase up to an additional 15% of the ADS, a strategy that not only provides flexibility in the offering but may also enhance fundraising capabilities to support its R&D projects.
- Use of Proceeds: The net proceeds from the offering will be used for potential drug commercialization, clinical research, and development expenses, particularly related to ulcerative colitis and Crohn's disease, indicating the company's strategic focus in the therapeutic area.
- Market Reaction: Abivax stock previously surged on positive clinical data but also faced a 32% drop due to safety concerns, and this offering may help stabilize the company's financial position and bolster market confidence.
See More
Semiconductor Stocks Surge; Watts Water Upgraded
- Semiconductor ETF Performance: The VanEck Semiconductor ETF (SMH) is on track for a 70% surge in Q2, driving chip stocks higher, with Astera Labs up 7%, KLA Corp up 8%, and Applied Materials up 5%, indicating strong market confidence in the semiconductor sector.
- Watts Water Upgrade: Watts Water Technologies jumped over 7% after Barclays upgraded its rating to overweight, as the company is seen as best positioned to benefit from the data center capital expenditures cycle with its expanding portfolio in waste and water technology.
- Abivax Stock Surge: U.S.-traded shares of French biotech company Abivax soared 40% after releasing new data on its ulcerative colitis treatment, showing malignancy rates in line with expectations and over 37% of initially non-responsive patients achieving clinical remission after about 10 months, highlighting treatment efficacy.
- Air Products Project Cancellation: Air Products and Chemicals rose over 8% after announcing it would not proceed with its Louisiana Clean Energy Complex, which is expected to incur up to $2.9 billion in pretax charges, reflecting the company's stringent financial return criteria.
See More
Abivax SA Shares Surge on Positive Phase 3 Data for Ulcerative Colitis
- Clinical Data Breakthrough: Abivax SA reported positive topline supplemental data from its Phase 3 ulcerative colitis maintenance program, revealing that 37.2% of induction non-responders achieved clinical remission and 34.5% achieved endoscopic remission at Week 44 following continued 50 mg treatment, significantly enhancing treatment efficacy in a highly refractory patient population.
- Dose Adjustment Strategy: Dose escalation to 50 mg of obefazimod recaptured clinical remission in 45.5% of patients who relapsed during ABTECT Maintenance Part 1, supporting a practical dose-escalation strategy for regaining and sustaining disease control over time, thereby enhancing the treatment's feasibility.
- Safety Data Boosts Confidence: The expanded cumulative safety data further strengthens confidence in the long-term safety profile of obefazimod, with CEO Marc de Garidel emphasizing that this reinforces the favorable benefit-risk profile for the program as they prepare for the planned NDA submission later this year.
- Positive Stock Reaction: Abivax SA shares surged 27% in early trading, reflecting the market's positive response to the new data and indicating investor confidence in the company's future potential.
See More
Abivax Shares Surge 25% on Positive Drug Trial Data
- Stock Recovery: Shares of French biotech company Abivax surged 25% on Tuesday, successfully reversing a 44% drop earlier this month due to clinical trial data concerns, indicating a regained market confidence in its drug prospects.
- Clinical Trial Results: The latest late-stage trial data revealed that obefazimod's remission rates for ulcerative colitis patients were in line with expected background rates, alleviating investor fears regarding cancer risks, although uncertainties remain.
- Analyst Insights: Jefferies analysts described the update as 'supportive,' yet expressed skepticism about whether it would restore investor confidence, citing the difficulty in discounting cancer risks and challenges related to cash needs and sparse catalyst pathways.
- Acquisition Potential: Abivax is viewed as a prime acquisition target, with unverified rumors suggesting interest from several Big Pharma companies, further enhancing its strategic significance in the biotech landscape.
See More
Abivax Raises Price Target and Launches $600 Million Public Offering
- Price Target Increase: BTIG raised its price target for Abivax from $150 to $175 while maintaining a Buy rating, reflecting confidence in the new drug obefazimod's safety data, indicating a potential upside of about 31% from the current stock price.
- FDA Risk Concerns: Wedbush analyst increased the price target from $90 to $110 but kept a Neutral rating due to concerns about how the FDA will assess cancer risk and the potential for a Black Box warning, suggesting a possible downside of around 17% from the stock's closing price.
- Public Offering Announcement: Abivax announced the launch of an underwritten public offering of approximately $600 million in American Depositary Shares, intending to use the net proceeds for U.S. commercialization and clinical development of obefazimod, indicating a proactive approach to future growth.
- Positive Market Sentiment: On Stocktwits, retail sentiment around ABVX remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', reflecting investor confidence in the company's ability to move forward independently and expectations for a potential buyout.
See More
Abivax Launches $600 Million Public Offering of ADS
- Offering Size: Abivax has announced the launch of a public offering of approximately $600 million (about €527 million) of American Depositary Shares (ADS), indicating the company's proactive approach to capital raising aimed at supporting its drug development and commercialization efforts.
- Share Issuance: The offering will be conducted through a capital increase without preferential subscription rights, which is expected to attract investor interest, particularly given the positive progress of the company's drug candidates in clinical trials.
- Use of Proceeds: The company intends to use the net proceeds from the offering for the commercialization of its lead drug candidate, obefazimod, clinical research, and general corporate purposes, reflecting its focus on future market opportunities.
- Market Response: The final size and pricing of the offering will be determined during the upcoming book-building process, with market conditions influencing the timing of completion, demonstrating the company's sensitivity to market dynamics.
See More
Abivax Launches $600 Million Underwritten Public Offering
- Offering Size: Abivax SA announced a public offering of approximately $600 million of American Depositary Shares (ADS), each with a nominal value of €0.01, reflecting the company's confidence in capital markets and its aim to raise funds for future growth.
- Underwriter Option: The company expects to grant underwriters an option to purchase up to an additional 15% of the ADS, a strategy that not only provides flexibility in the offering but may also enhance fundraising capabilities to support its R&D projects.
- Use of Proceeds: The net proceeds from the offering will be used for potential drug commercialization, clinical research, and development expenses, particularly related to ulcerative colitis and Crohn's disease, indicating the company's strategic focus in the therapeutic area.
- Market Reaction: Abivax stock previously surged on positive clinical data but also faced a 32% drop due to safety concerns, and this offering may help stabilize the company's financial position and bolster market confidence.
See More
Semiconductor Stocks Surge; Watts Water Upgraded
- Semiconductor ETF Performance: The VanEck Semiconductor ETF (SMH) is on track for a 70% surge in Q2, driving chip stocks higher, with Astera Labs up 7%, KLA Corp up 8%, and Applied Materials up 5%, indicating strong market confidence in the semiconductor sector.
- Watts Water Upgrade: Watts Water Technologies jumped over 7% after Barclays upgraded its rating to overweight, as the company is seen as best positioned to benefit from the data center capital expenditures cycle with its expanding portfolio in waste and water technology.
- Abivax Stock Surge: U.S.-traded shares of French biotech company Abivax soared 40% after releasing new data on its ulcerative colitis treatment, showing malignancy rates in line with expectations and over 37% of initially non-responsive patients achieving clinical remission after about 10 months, highlighting treatment efficacy.
- Air Products Project Cancellation: Air Products and Chemicals rose over 8% after announcing it would not proceed with its Louisiana Clean Energy Complex, which is expected to incur up to $2.9 billion in pretax charges, reflecting the company's stringent financial return criteria.
See More
Abivax SA Shares Surge on Positive Phase 3 Data for Ulcerative Colitis
- Clinical Data Breakthrough: Abivax SA reported positive topline supplemental data from its Phase 3 ulcerative colitis maintenance program, revealing that 37.2% of induction non-responders achieved clinical remission and 34.5% achieved endoscopic remission at Week 44 following continued 50 mg treatment, significantly enhancing treatment efficacy in a highly refractory patient population.
- Dose Adjustment Strategy: Dose escalation to 50 mg of obefazimod recaptured clinical remission in 45.5% of patients who relapsed during ABTECT Maintenance Part 1, supporting a practical dose-escalation strategy for regaining and sustaining disease control over time, thereby enhancing the treatment's feasibility.
- Safety Data Boosts Confidence: The expanded cumulative safety data further strengthens confidence in the long-term safety profile of obefazimod, with CEO Marc de Garidel emphasizing that this reinforces the favorable benefit-risk profile for the program as they prepare for the planned NDA submission later this year.
- Positive Stock Reaction: Abivax SA shares surged 27% in early trading, reflecting the market's positive response to the new data and indicating investor confidence in the company's future potential.
See More
